Metformin for the treatment of hidradenitis suppurativa: A little help along the way

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 9, 2013, Pages 1101-1108

  Verdolini, R ^a   Clayton, N ^b   Smith, A ^b   Alwash, N ^a   Mannello, B ^c  

^a PRINCESS ALEXANDRA HOSPITAL NHS TRUST   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c Mannello Statistics   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DAPSONE; ETRETIN; METFORMIN; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DERMATOLOGY LIFE QUALITY INDEX; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SUPPURATIVE HIDRADENITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; METFORMIN; MIDDLE AGED; YOUNG ADULT;

EID: 84881168250     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04668.x     Document Type: Article

References (49)

1. Shah N,. Hidradenitis suppurativa: a treatment challenge. Am Fam Physician 2005; 72: 1547-1552.
2. Brown TJ, Rosen T, Orengo IF,. Hidradenitis suppurativa. South Med J 1998; 91: 1107-1114.
3. Wolkenstein P,. Quality of life in hidradenitis suppurativa. In:, Jemec GB, Revuz J, Leyden J, eds. Hidradenitis Suppurativa. Berlin, Germany: Springer, 2006: 116-119.
4. Jansen I, Altmeyer P, Piewig G,. Acne inversa (alias hidradenitissuppurativa). J Eur Acad Dermatol Venereol 2001; 15: 532-540.
5. Lee RA, Yoon A, Kist J,. Hidradenitissuppurativa: an update. Adv Dermatol 2007; 23: 289-306.
6. Wiseman MC,. Hidradenitis suppurativa: a review. Dermatol Ther 2004; 17: 50-54.
7. Mendonça CO, Griffiths CE,. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 2006; 154: 977-978.
8. Jemec GB,. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacothe 2004; 5: 1767-1770.
9. Yu CC, Cook MG,. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122: 763-769.
10. Boer J, Weltevreden EF,. Hidradenitissuppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol 1996; 135: 721-725.
11. Jemec GB, Hansen U,. Histology of hidradenitissuppurativa. J Am Acad Dermatol 1996; 34: 994-999.
12. Attanoos RL, Appleton MA, Douglas-Jones AG,. The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br J Dermatol 1995; 133: 254-258.
13. Gao M, Wang PG, Cui Y, Yang S, Zhang YH, Lin D, Zhang KY, Liang YH, Sun LD, Yan KL, Xiao FL, Huang W, Zhang XJ,. Inversa acne (hidradenitissuppurativa): a case report and identification of the locus at chromosome 1p21.1-1q25.3. J Invest Dermatol 2006; 126: 1302-1306.
14. Sellheyer K, Krahl D,. 'Hidradenitissuppurativa' is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol 2005; 44: 535-540.
15. Kamp S, Fiehn AM, Stenderup K, Rosada C, Pakkenberg B, Kemp K, Dam TN, Jemec GB,. Hidradenitissuppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol 2011; 164: 1017-1022.
16. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ, Brightbill HD, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL,. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169: 1535-1541.
17. Lapins J, Asman B, Gustafsson A, Bergstrom K, Emtestam L,. Neutrophil-related host response in hidradenitis suppurativa: a pilot study in patients with inactive disease. Acta Derm Venereol 2001; 81: 96-99.
18. Hunger RE, Surovy AM, Hassan AS, Braathen LR, Yawalkar N,. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br J Dermatol 2008; 158: 691-697.
19. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD,. Severe hidradenitissuppurativa treated with infliximab infusion. Arch Dermatol 2003; 139: 1540-1542.
20. Haslund P, Lee RA, Jemec GB,. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol 2009; 89: 595-600.
21. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA,. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-217.
22. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB,. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 2011; 165: 391-398.
23. Adams DR, Yankura JA, Fogelberg AC, Anderson BE,. Treatment of hidradenitissuppurativa with etanercept injection. Arch Dermatol 2010; 146: 501-504.
24. Barth H, Layton AM, Cunliffe WJ,. Endocrine factors in pre- and postmenopausal women with hidradenitissuppurativa. Br J Dermatol 1996; 134: 1057-1059.
25. Mortimer PS, Dawber RP, Gales MA, Moore RA,. Mediation of hidradenitis suppurativa by androgens. Br Med J (Clin Res Ed) 1986; 292: 245-248.
26. Barth H, Kealey T,. Androgen metabolism by isolated human axillary apocrine glands in hidradenitissuppurativa. Br J Dermatol 1991; 125: 304-308.
27. Jemec GB,. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol 1988; 119: 345-350.
28. Hofer T, Itin PH,. Acne inversa: a dapsone-sensitive dermatosis. Hautarzt 2001; 52 (10 Pt 2): 989-992.
29. Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, Garrett S,. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007; 56: 43. 1-10
30. Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GB,. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology 2011; 222: 342-346.
31. Lam J, Krakowski AC, Friedlander SF,. Hidradenitissuppurativa (acne inversa): management of a recalcitrant disease. Pediatr Dermatol 2007; 24: 465-473.
32. Slade DE, Powell BW, Mortimer PS,. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 2003; 56: 451-461.
33. Mortimer PS, Dawber RP, Gales MA, Moore RA,. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitissuppurativa. Br J Dermatol 1986; 115: 263-268.
34. Joseph MA, Jayaseelan E, Ganapathi B, Stephen J,. Hidradenitissuppurativa treated with finasteride. J Dermatolog Treat 2005; 16: 75-78.
35. Zeligman I,. Temporary x-ray epilation therapy of chronic axillary hidradenitissuppurativa. Arch Dermatol 1965; 92: 690-694.
36. Schenck SG,. Hidradenitissuppurativaaxillaris; an analysis of 54 cases treated with roentgen rays. Radiology 1950; 54: 74-77.
37. O'Reilly DJ, Pleat JM, Richards AM,. Treatment of hidradenitissuppurativa with botulinum toxin A. Plast Reconstr Surg 2005; 116: 1575-1576.
38. Gold M, Bridges TM, Bradshaw VL, Boring M,. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol 2004; 3 (Suppl. 1): S32-S35.
39. Gold MH,. Aminolevulinic acid photodynamic therapy for hidradenitis suppurativa. Dermatol Clin 2007; 25: 67-73.
40. Lapins J, Sartorius K, Emtestam L,. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitissuppurativa. J Am Acad Dermatol 2002; 47: 280-285.
41. Rompel R, Petres J,. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2000; 26: 638-643.
42. Meixner D, Schneider S, Krause M, Sterry W,. Acne inversa. J Dtsch Dermatol Ges 2008; 6: 189-196.
43. Sartorius K, Lapins J, Emtestam L, Jemec GB,. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003; 149: 211-213.
44. Tsilchorozidou T, Prelevic GM,. The role of metformin in the management of polycystic ovary syndrome. Curr Opin Obstet Gynecol 2003; 15: 483-488.
45. Lebinger TG,. Metformin and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2007; 14: 132-140.
46. Stadtmauer LA, Wong BC, Oehninger S,. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome-beyond ovulation induction. Hum Reprod 2002; 17: 3016-3026.
47. Kraft JN, Searles GE,. Hidradenitissuppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 2007; 11: 125-131.
48. Ben-Haroush A, Yogev Y, Fisch B,. Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004; 115: 125-133.
49. Massin N, Galey J, Basille C, Théron-Gérard L, Bry-Gauillard H, Cédrin-Durnerin I, Hugues JN,. Should infertile women with polycystic ovarian syndrome be treated with metformine?. Gynecol Obstet Fertil 2003; 31: 265-274.